Delivery Order SPE2DB20D3303-SPE2DB25FA3YV
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 180 tablets of Sacubitril-Valsartan 97-103 mg, with a contract ceiling value of $1,066.02. This is a firm fixed-price delivery order with an award date of September 5, 2025, and ultimate completion date of September 8, 2025. The contract was competitively awarded without set-aside designation, and performance will be executed at AmerisourceBergen's Conshohocken, Pennsylvania location. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $3,938.25 to AmerisourceBergen Drug Corp for Sacubitril-Valsartan 24-26 mg tablets (60-count supply) on September 22, 2025, with an ultimate completion date of September 23, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a single delivery order under...
- The Defense Logistics Agency awarded a delivery order valued at $2,160.00 to AmerisourceBergen Drug Corp for Sacubitril-Valsartan 97-103 mg tablets (60-count units) on August 7, 2025, with completion expected by August 8, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a pharmaceutical supply delivery supporting federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Sacubitril-Valsartan 24-26 mg tablets in a quantity of 180 units, valued at $19,641.70. This delivery order is issued under a firm fixed-price contract type with no set-aside designation, indicating the award was competitively procured. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Sacubitril-Valsartan 24-26 mg tablets (60-count) valued at $2,202.57. This is a firm fixed-price, non-set-aside contract with performance to be completed by September 16, 2025, and fulfillment occurring at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award represents a delivery order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $44,508.93 delivery order to AmerisourceBergen Drug Corp for the supply of Sacubitril-Valsartan 49-51 mg tablets (180-count supply) under a firm fixed price contract structure. The award was issued on September 5, 2025, with an ultimate completion date of September 8, 2025, and represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this order at its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $18,186.68 to AmerisourceBergen Drug Corp for the supply of Sacubitril-Valsartan 24-26 mg tablets (60 count) on September 9, 2025, with a completion date of September 10, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Sacubitril-Valsartan 24-26 mg in 60-count quantities, with a contract ceiling value of $10,688.40. This firm fixed price delivery order, which carries an ultimate completion date of August 21, 2025, represents a competitively awarded, non-set-aside procurement supporting federal medical supply requirements. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a $2,703.46 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Sacubitril-Valsartan 24-26 mg tablets (60-count). This is a non-set-aside, competitively awarded contract with an ultimate completion date of August 5, 2025, and performance location in Conshohocken, Pennsylvania. The delivery order represents a small-value transaction typical of AmerisourceBergen's ongoing pharmaceutical supply operations...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,741.44 to AmerisourceBergen Drug Corp for the supply of Sacubitril-Valsartan 24-26 mg in quantities of 60 tablets. This competitively awarded, firm fixed-price delivery order was issued on September 17, 2025, with an ultimate completion date of September 18, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA3YVDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $15,166.08 for Sacubitril-Valsartan 97-103 mg tablets (60-count) on September 22, 2025, with completion scheduled for September 23, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal medical supply needs. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. That prime contract vehicle serves as a comprehensive global pharmaceutical support mechanism enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. The company's extensive federal contract portfolio with DLA demonstrates its established capability to fulfill competitive federal pharmaceutical procurement requirements across multiple therapeutic categories.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.2k | 9/22/25 |